Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$394.3M
59M shares
52-week range
$3.27 – $6.95
88% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
www.foghorntx.comNo one on the platform currently holds FHTX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 406,425 | $1.9M |
No one on the platform has traded FHTX yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
💥 New Week 34 MDA breakout picks released today in advance for members after the close while S&P 500 $SPY intraday road map continues in Segment 4 chop with Sector Gauges divided. 💥 Week 33 MDA picks with 3 out of 4 selections beating 10% gains in less than a week led by $FHTX $TIC with peak gains so far over +21%. 💥 MDA breakouts average cumulative return +168.3% YTD extending the count to 377 weeks with at least one pick gaining over 10% in less than a week... 3 of 4 so far this week.
View on StockTwits ↗🌟 $FHTX becomes the 3rd of 4 picks for Week 33 to break 10% for members through Monday. Extending the count to 377 weeks with at least one weekly pick gaining over 10% in less than a week. 🌟 Week 33 MDA picks are up +11.4% through Monday with all picks positive. Increasing the average cumulative weekly breakout returns to +169.4% YTD. 💥 Up to 12,600 daily picks per year available on the automated http://vmbreakouts.com website with prior free samples at http://top.vmbreakouts.com
View on StockTwits ↗$FHTX $GSK $LLY $SLS $VKTX Has nothing to do with any of the other tickers. Stop spamming @Stocktwits reporting. BLOCKED!
View on StockTwits ↗$GSK $FHTX $SLS $LLY $VKTX a big move up at Foghorn for the Mir onco-protein degrader (Lily partnered) maybe something starting to form there. Just placing heads up as Foghorn a sleeper last 6 months or so.
View on StockTwits ↗$FHTX wondering how folks felt about FHD-909/LY4050784 when prelude tried the SMARCA2 target before and showed underwhelming results? Are they mainly focusing on combination strategy with keytruda for esophageal/lung?
View on StockTwits ↗$OMEX Shorters running out of Ammo, mega short squeeze soon just like $VRXA $SKIN $FHTX
View on StockTwits ↗$FHTX a little quite for a 🔥 day. Love this one and been in for a bit. Timing has come.
View on StockTwits ↗$FHTX ratified its 2026 annual meeting, electing three directors and approving Deloitte & Touche as auditor.
View on StockTwits ↗Next-Generation DNA Repair Therapies Open New Frontiers in Oncology ONCO.AQL $ONNVF $AZN $APRE $BOLD $FHTX https://ibn.fm/zrVjp
View on StockTwits ↗@LabPsycho degraders portfolio $CCCC $PRLD $ARVN $FHTX $NRIX (all likely to go down a lot with XBI dip)
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $29M | -9.6% | $-1.03 | $-1.30–$-0.82 | — | 7 |
| 2027 | $35M | +21.3% | $-0.99 | $-1.11–$-0.80 | — | 7 |
| 2028 | $54M | +56.2% | $-0.60 | $-1.15–$0.32 | — | 6 |
| 2029 | $68M | +25.4% | $-0.52 | $-0.96–$-0.13 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.24 | $-0.10 | +59.2% |
| 2026-05-07 | $-0.28 | $-0.29 | -3.6% |
| 2026-03-11 | $-0.28 | $-0.34 | -21.4% |
| 2025-11-05 | $-0.31 | $-0.25 | +19.4% |
| 2025-08-05 | $-0.31 | $-0.28 | +9.7% |
| 2025-05-14 | $-0.30 | $-0.30 | +0.0% |
| 2025-03-06 | $-0.43 | $-0.30 | +30.2% |
| 2024-11-04 | $-0.42 |
| $-0.31 |
| +26.2% |
| $92M |
| — |
| IMRXImmuneering Corporation | $5.20 | +2.56% | $189M | — |
| PYXSPyxis Oncology, Inc. | $3.01 | -5.35% | $191M | — |
Source: Financial Modeling Prep · peers by sector/industry